News List

Holiday Notice of Mid-Autumn Festival
2019-09-11

To all departments and all employees:According to the related provisions on national holidays &

CPhI North America 2020 in Philadelphia USA Booth#1506
2019-08-26

FluoroPharm will exhibit CPhI North America 2020 in Pennsylvania Convention Center,Philadelphia, PA,

FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
2019-08-19

The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib),

The 150 millionth chemical substance was born!
2019-08-07

According to the American Chemical and Engineering News (C&EN), the American Chemical Abstracts

FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
2019-07-12

Novartis today announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib)

New drug delivery method, FDA approved a new epilepsy treatment
2019-06-29

UCB announced that the USFDA has approved Nayzilam (midazolam) nasal spray for the acute treatment o

Holiday Notice of Dragon Boat Festival
2019-06-01

To all departments and employees:According to the related national legal & the actual situation

Long-term anti-AIDS, Combination of two schemes submits application
2019-05-29

On April 29, 2019,the anti-AIDS long-acting two-party “cabotegravir + Ripirilin”submitted to the FDA

For the initial treatment of HIV patients, the FDA approved the first dual-agent combination therapy
2019-04-27

Today, the US FDA announced that it has approved the listing of the antiviral therapy Dovato (dolute

Novartis‘s Multiple sclerosis Innovative drug approved
2019-03-29

Recently, US FDA announced approved the listing of Mayzent (siponimod) developed by Novartis, for th